Literature DB >> 2210776

Monoclonal antibodies to complement components without the need of their prior purification. II. Antibodies to mouse C3 and C4.

E Kremmer1, S Thierfelder, E Felber, G Hoffmann-Fezer, M Wasiliu.   

Abstract

Rat monoclonal antibodies (MAbs) to mouse complement components C3 and C4 were produced by immunizing rats with cell-bound C3 and C4. This principle involves: a) using mouse thymocytes coated with syngeneic rat antibody isotypes that show high affinity to C1q, b) the intercalation of C1q from serum and c) the subsequent activation of the classical complement pathway leading to deposition of cell-bound complement components. Screening for anti-complement antibodies was performed on antibody coating microtiter plates with mouse serum as source of complement. The reactivity of the MAbs was determined by variations of the ELISA screening system using EDTA-serum to inhibit complement activation by C1 dissociation, serum rendered deficient of functionally active C3 by treatment with cobra venom factor (CVF) or serum of genetically C5-deficient mice. The specificity of the MAbs was confirmed by affinity chromatography followed by SDS-PAGE and immunoblotting. We were able to establish a panel of anti-C3 and anti-C4 MAbs of various isotypes.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2210776     DOI: 10.1089/hyb.1990.9.309

Source DB:  PubMed          Journal:  Hybridoma        ISSN: 0272-457X


  2 in total

1.  Complement C3 and C4 expression in C1q sufficient and deficient mouse models of Alzheimer's disease.

Authors:  Jun Zhou; Maria I Fonseca; Karntipa Pisalyaput; Andrea J Tenner
Journal:  J Neurochem       Date:  2008-07-09       Impact factor: 5.372

2.  Combination of factor H mutation and properdin deficiency causes severe C3 glomerulonephritis.

Authors:  Allison M Lesher; Lin Zhou; Yuko Kimura; Sayaka Sato; Damodar Gullipalli; Andrew P Herbert; Paul N Barlow; Hannes U Eberhardt; Christina Skerka; Peter F Zipfel; Takayuki Hamano; Takashi Miwa; Kenneth S Tung; Wen-Chao Song
Journal:  J Am Soc Nephrol       Date:  2012-11-30       Impact factor: 10.121

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.